Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz

Ali Mcbride, Sanjeev Balu, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo L Abraham

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: Biosimilar medicines offer significant cost-savings potential over their reference products, which can be re-allocated to provide access to other cancer treatments on a budget-neutral basis. Methods: Simulation study using cost data for the USA under consideration of several prophylaxis patterns. Results: Potential savings from conversion from reference filgrastim to biosimilar filgrastim-sndz are significant. These savings expand budget-neutral access to novel immunotherapies (obinutuzumab; pembrolizumab) or supportive care (filgrastim-sndz). Conclusion: The combination of biosimilar savings and expanded access increases the value of cancer care as the same supportive care is provided at lower cost, additional cancer care is enabled at no additional cost, and more patients will have access to cancer care.

Original languageEnglish (US)
Pages (from-to)2285-2295
Number of pages11
JournalFuture Oncology
Volume13
Issue number25
DOIs
StatePublished - Oct 1 2017

Fingerprint

Biosimilar Pharmaceuticals
Neutropenia
Budgets
Costs and Cost Analysis
Neoplasms
Cost Savings
Therapeutics
Immunotherapy
Filgrastim

Keywords

  • biosimilars
  • neutropenia
  • pharmacoeconomics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. / Mcbride, Ali; Balu, Sanjeev; Campbell, Kim; Bikkina, Mohan; MacDonald, Karen; Abraham, Ivo L.

In: Future Oncology, Vol. 13, No. 25, 01.10.2017, p. 2285-2295.

Research output: Contribution to journalArticle

Mcbride, Ali ; Balu, Sanjeev ; Campbell, Kim ; Bikkina, Mohan ; MacDonald, Karen ; Abraham, Ivo L. / Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. In: Future Oncology. 2017 ; Vol. 13, No. 25. pp. 2285-2295.
@article{5be69d5ab34041fd9e99eb92c19ff168,
title = "Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz",
abstract = "Aim: Biosimilar medicines offer significant cost-savings potential over their reference products, which can be re-allocated to provide access to other cancer treatments on a budget-neutral basis. Methods: Simulation study using cost data for the USA under consideration of several prophylaxis patterns. Results: Potential savings from conversion from reference filgrastim to biosimilar filgrastim-sndz are significant. These savings expand budget-neutral access to novel immunotherapies (obinutuzumab; pembrolizumab) or supportive care (filgrastim-sndz). Conclusion: The combination of biosimilar savings and expanded access increases the value of cancer care as the same supportive care is provided at lower cost, additional cancer care is enabled at no additional cost, and more patients will have access to cancer care.",
keywords = "biosimilars, neutropenia, pharmacoeconomics",
author = "Ali Mcbride and Sanjeev Balu and Kim Campbell and Mohan Bikkina and Karen MacDonald and Abraham, {Ivo L}",
year = "2017",
month = "10",
day = "1",
doi = "10.2217/fon-2017-0374",
language = "English (US)",
volume = "13",
pages = "2285--2295",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "25",

}

TY - JOUR

T1 - Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz

AU - Mcbride, Ali

AU - Balu, Sanjeev

AU - Campbell, Kim

AU - Bikkina, Mohan

AU - MacDonald, Karen

AU - Abraham, Ivo L

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Aim: Biosimilar medicines offer significant cost-savings potential over their reference products, which can be re-allocated to provide access to other cancer treatments on a budget-neutral basis. Methods: Simulation study using cost data for the USA under consideration of several prophylaxis patterns. Results: Potential savings from conversion from reference filgrastim to biosimilar filgrastim-sndz are significant. These savings expand budget-neutral access to novel immunotherapies (obinutuzumab; pembrolizumab) or supportive care (filgrastim-sndz). Conclusion: The combination of biosimilar savings and expanded access increases the value of cancer care as the same supportive care is provided at lower cost, additional cancer care is enabled at no additional cost, and more patients will have access to cancer care.

AB - Aim: Biosimilar medicines offer significant cost-savings potential over their reference products, which can be re-allocated to provide access to other cancer treatments on a budget-neutral basis. Methods: Simulation study using cost data for the USA under consideration of several prophylaxis patterns. Results: Potential savings from conversion from reference filgrastim to biosimilar filgrastim-sndz are significant. These savings expand budget-neutral access to novel immunotherapies (obinutuzumab; pembrolizumab) or supportive care (filgrastim-sndz). Conclusion: The combination of biosimilar savings and expanded access increases the value of cancer care as the same supportive care is provided at lower cost, additional cancer care is enabled at no additional cost, and more patients will have access to cancer care.

KW - biosimilars

KW - neutropenia

KW - pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=85034103605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034103605&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0374

DO - 10.2217/fon-2017-0374

M3 - Article

C2 - 28870106

AN - SCOPUS:85034103605

VL - 13

SP - 2285

EP - 2295

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 25

ER -